M
GLUE
Monte Rosa Therapeutics, Inc.
18.98
-0.18-0.94%After Hours: 19.30 +0.32 +1.69%17:32 02/20 EST
OPEN/PREV CLOSE18.92/19.16
TODAY RANGE18.43-19.43
VOL882.75K
MARKET CAP1.45B
52 WEEK RANGE3.500-25.77
AVG VOL (3M)1.61M
% TURNOVER1.16%
TURNOVER--
P/E (TTM)75.77
% RANGE5.17%
EPS(TTM)0.2505
P/E(FORWARD)-60.0234
P/B4.771
BVPS3.979
DIVIDEND--
P/S15.44
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.43B
SHARES OUTSTANDING76.24M
NEXT EARNINGS03/18-03/23
FREE FLOAT75.53M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·02/14 12:37
The Market Doesn't Like What It Sees From Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Revenues Yet As Shares Tumble 26%
TipRanks·02/11 21:40
Monte Rosa Therapeutics files automatic mixed securities shelf
Reuters·02/10 21:02
Monte Rosa Therapeutics Appoints Matthew Bowen as Corporate Controller
Simply Wall St·01/21 03:27
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Positive MRT-8102 Phase 1 Interim Data
Barron‘s·01/17 01:39
13D Filings
Simply Wall St·01/15 03:25
The Bull Case For Monte Rosa Therapeutics (GLUE) Could Change Following MRT-8102 Data And $300 Million Raise
TipRanks·01/14 11:50
Monte Rosa Therapeutics price target raised to $37 from $27.50 at Piper Sandler
TipRanks·01/09 22:05
Monte Rosa Therapeutics Prices $300 Million Public Offering
Reuters·01/09 21:06
Monte Rosa Therapeutics CEO Markus Warmuth Reports Sale of Common Shares
Same Industry
Name/Symbol
Change%
Price